EG24463A - Modified release pharmaceutical composition - Google Patents

Modified release pharmaceutical composition

Info

Publication number
EG24463A
EG24463A EG142999A EG142999A EG24463A EG 24463 A EG24463 A EG 24463A EG 142999 A EG142999 A EG 142999A EG 142999 A EG142999 A EG 142999A EG 24463 A EG24463 A EG 24463A
Authority
EG
Egypt
Prior art keywords
pharmaceutical composition
modified release
release pharmaceutical
modified
composition
Prior art date
Application number
EG142999A
Other languages
English (en)
Inventor
Robert Glinecke
Susan Marie Milosovich
William Muldoon
Vincenzo Re
Joseph Sauer
Janet Louise Skinner
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of EG24463A publication Critical patent/EG24463A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
EG142999A 1998-11-12 1999-11-11 Modified release pharmaceutical composition EG24463A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
EG24463A true EG24463A (en) 2009-07-16

Family

ID=26314667

Family Applications (2)

Application Number Title Priority Date Filing Date
EG142999A EG24463A (en) 1998-11-12 1999-11-11 Modified release pharmaceutical composition
EG142899A EG22344A (en) 1998-11-12 1999-11-11 Process for preparing of novel pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
EG142899A EG22344A (en) 1998-11-12 1999-11-11 Process for preparing of novel pharmaceutical composition

Country Status (39)

Country Link
EP (3) EP1815855A1 (fr)
JP (1) JP2002529505A (fr)
KR (2) KR20060097140A (fr)
CN (1) CN1289081C (fr)
AP (2) AP2008004490A0 (fr)
AR (2) AR023699A1 (fr)
AT (1) ATE382352T1 (fr)
AU (1) AU768578B2 (fr)
BG (2) BG65444B1 (fr)
BR (1) BR9915215A (fr)
CA (1) CA2350659C (fr)
CO (1) CO5190673A1 (fr)
CY (1) CY1107909T1 (fr)
CZ (1) CZ20011628A3 (fr)
DE (1) DE69937898T2 (fr)
DK (1) DK1128827T3 (fr)
DZ (1) DZ2937A1 (fr)
EA (3) EA200702648A1 (fr)
EG (2) EG24463A (fr)
ES (1) ES2299269T3 (fr)
HK (1) HK1040909B (fr)
HR (2) HRP20010342B1 (fr)
HU (1) HUP0104307A3 (fr)
ID (1) ID29344A (fr)
IL (2) IL143003A0 (fr)
MY (1) MY135973A (fr)
NO (1) NO20012351L (fr)
NZ (2) NZ526440A (fr)
OA (1) OA11676A (fr)
PE (1) PE20001428A1 (fr)
PL (1) PL198717B1 (fr)
PT (1) PT1128827E (fr)
RS (1) RS50208B (fr)
SI (1) SI1128827T1 (fr)
SK (1) SK286937B6 (fr)
TR (2) TR200503846T2 (fr)
TW (2) TWI257305B (fr)
UY (2) UY25798A1 (fr)
WO (1) WO2000028990A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
MXPA02009478A (es) * 2001-01-31 2003-03-10 Roehm Gmbh Forma medicinal de multiples particulas que comrpende por lo menos dos formas de bolitas recubiertas de diferente manera.
US20050107450A1 (en) * 2001-12-21 2005-05-19 Brown Kathleen K. Dosing regimen for ppar-gamma activators
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
CA2492722A1 (fr) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
CA2514879C (fr) * 2003-01-03 2014-09-16 Shire Laboratories Inc. Utilisation d'un melange de deux ou de plusieurs matieres d'enrobage enteriques afin de reguler la liberation de medicaments
AU2004208606B2 (en) 2003-01-29 2009-09-24 Takeda Pharmaceutical Company Limited Process for producing coated preparation
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US10016370B2 (en) * 2011-07-14 2018-07-10 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
CA3018328A1 (fr) 2014-10-31 2016-04-30 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Agents hypoglycemiques de thiazolidinedione
WO1989008651A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiaxolidinedione hypoglycemiques
WO1991007107A1 (fr) 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT65619A (en) 1990-07-03 1994-07-28 Yamanouchi Pharma Co Ltd Process for producing bisheterocyclic compounds and pharmaceutical preparations containing them
AU645112B2 (en) 1990-08-23 1994-01-06 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
DK0579733T3 (da) 1991-04-11 2001-10-15 Upjohn Co Thiazolidindionderivater, fremstilling og anvendelse deraf
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (fr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および2型糖尿病の治療におけるそれらの使用
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
PL176885B1 (pl) 1992-07-03 1999-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2001521551A (ja) * 1997-03-24 2001-11-06 ガルデルマ リサーチ アンド デヴェロップメント エス エヌ セ インスリン非依存性糖尿病の治療のためのレチノイド関連分子

Also Published As

Publication number Publication date
CA2350659C (fr) 2009-06-09
NO20012351D0 (no) 2001-05-11
CN1289081C (zh) 2006-12-13
ATE382352T1 (de) 2008-01-15
NZ526440A (en) 2005-01-28
EG22344A (en) 2002-12-31
PT1128827E (pt) 2008-03-10
PL348153A1 (en) 2002-05-06
HUP0104307A2 (hu) 2002-07-29
EP1128827B1 (fr) 2008-01-02
EP1815855A1 (fr) 2007-08-08
TWI246920B (en) 2006-01-11
AP1901A (en) 2008-10-24
CA2350659A1 (fr) 2000-05-25
CO5190673A1 (es) 2002-08-29
AR023700A1 (es) 2002-09-04
CZ20011628A3 (cs) 2001-12-12
HK1040909B (zh) 2008-08-01
BR9915215A (pt) 2001-07-31
AR023699A1 (es) 2002-09-04
NZ511611A (en) 2003-10-31
RS50208B (sr) 2009-07-15
DZ2937A1 (fr) 2004-03-15
HUP0104307A3 (en) 2003-12-29
PL198717B1 (pl) 2008-07-31
EA200702648A1 (ru) 2008-10-30
YU36401A (sh) 2004-05-12
UY25798A1 (es) 2000-12-29
TR200101337T2 (tr) 2001-11-21
CY1107909T1 (el) 2013-09-04
ID29344A (id) 2001-08-23
AU1272900A (en) 2000-06-05
BG105570A (en) 2002-02-28
JP2002529505A (ja) 2002-09-10
SK6432001A3 (en) 2001-12-03
EA200601144A1 (ru) 2007-02-27
AU768578B2 (en) 2003-12-18
TR200503846T2 (tr) 2007-01-22
HRP20010342B1 (en) 2008-04-30
ES2299269T3 (es) 2008-05-16
SI1128827T1 (sl) 2008-06-30
AP2008004490A0 (en) 2008-06-30
CN1333683A (zh) 2002-01-30
KR100732599B1 (ko) 2007-06-27
KR20010073229A (ko) 2001-07-31
DK1128827T3 (da) 2008-04-28
DE69937898D1 (de) 2008-02-14
HRP20010342A2 (en) 2002-06-30
IL183972A0 (en) 2007-10-31
EA200100540A1 (ru) 2001-10-22
PE20001428A1 (es) 2001-02-08
SK286937B6 (sk) 2009-07-06
TWI257305B (en) 2006-07-01
UY25800A1 (es) 2000-08-21
MY135973A (en) 2008-07-31
IL143003A0 (en) 2002-04-21
OA11676A (en) 2005-01-12
BG65444B1 (bg) 2008-08-29
HK1040909A1 (en) 2002-06-28
BG109893A (bg) 2008-11-28
EP1128827A1 (fr) 2001-09-05
TW200505436A (en) 2005-02-16
EP1917962A1 (fr) 2008-05-07
WO2000028990A1 (fr) 2000-05-25
NO20012351L (no) 2001-07-04
EA007608B1 (ru) 2006-12-29
KR20060097140A (ko) 2006-09-13
DE69937898T2 (de) 2009-01-02
HRP20080117A2 (en) 2008-10-31

Similar Documents

Publication Publication Date Title
HUP9901779A3 (en) Modified release multiple-units dosage composition
PL351387A1 (en) Pharmaceutical composition
HK1033649A1 (en) Extended release dosage form
HU9901606D0 (en) Pharmaceutical compositions
GB9827996D0 (en) Pharmaceutical Compositions
GB9706089D0 (en) Pharmaceutical composition
PT1466615E (pt) Composição farmacêutica
PL343769A1 (en) Pharmaceutical composition
EG24463A (en) Modified release pharmaceutical composition
GB9809213D0 (en) Pharmaceutical compositions
GB9818591D0 (en) Pharmaceutical composition
GB9717444D0 (en) Pharmaceutical composition
HUP0002455A3 (en) Gastric-retained pharmaceutical composition
GB9717428D0 (en) Pharmaceutical composition
EP1124557A4 (fr) Composition pharmaceutique
AP2000001878A0 (en) Pharmaceutical compositions
GB9806487D0 (en) Pharmaceutical compositions
GB9717770D0 (en) Pharmaceutical composition
GB2321190B (en) Pharmaceutical composition
HU9800078D0 (en) Pharmaceutical composition
GB9726781D0 (en) Pharmaceutical composition
GB9818233D0 (en) Pharmaceutical composition
HU9801772D0 (en) Pharmaceutical composition
GB9916413D0 (en) Pharmaceutical composition
GB9916210D0 (en) Pharmaceutical composition